Home · Sapphiros

Our mission is simple: to deliver the lowest cost, easy to use, scalable diagnostics providing access to all. Copied!

At Sapphiros, innovation has a purpose.

We bring together advanced science, intelligent design and scalable technology to make high-quality diagnostic testing accessible to all.

Our portfolio spans multiple platforms and products designed to deliver fast, accurate results that help people make informed choices and support stronger health systems around the world.

Together, we are creating a company where innovation thrives, people grow, and purpose drives everything.

Accessible, affordable and scalable health technology Copied!

Sapphiros is redefining global health through high-performance testing technologies that deliver rapid, reliable results -- supporting a wide range of health needs from infectious diseases and routine diagnostic testing to public health emergencies and future pandemics.

Making health knowledge effortless

Laboratory-quality accuracy at a fraction of the cost

Extreme Volume Manufacturing

UK-based extreme volume manufacturing (EVM) with global scale capability. Our next-generation automated facility has a capacity of five billion units.

Performance

Technologies that work in both advanced and resource-limited settings

Low cost

Low cost, high performance, user-friendly design

In the spotlight Copied!

Monday, December 1, 2025

BARDA announces collaboration with Sapphiros for the development of an OTC, single-use, low-cost digital antigen test

Together with Sapphiros, The US Biomedical Advanced Research and Development Authority (BARDA) is developing an over the counter (OTC), single-use, low-cost antigen test that can detect and differentiate between respiratory viruses.

Wednesday, November 19, 2025

Sapphiros announces a strategic agreement with Roche, providing Roche access to 1 billion lateral flow tests and access to future molecular point-of-care tests.

Agreement secures rapid, global access to tests for future pandemics and health emergencies. Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros’ 5 billion unit capacity proprietary manufacturing process.